Table 4 Immunohistochemical stains, EBER-ISH, and molecular studies.

From: Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics

 

Our study (n = 55)

Literature

Total cases of EB-LBCL (n = 202)

Japanese (n = 87)

Non-Japanese (n = 60)

Total literature (n = 147)

Immunophenotype

  CD45

40/43 (93%)

5/16 (31%)

10/13 (77%)

15/29 (52%)

55/72 (76%)

  CD20

53/54 (98%)

72/76 (95%)

57/60 (95%)

129/136 (95%)

182/190 (96%)

  BCL2

30/36 (83%)

12/14 (86%)

28/46 (61%)

40/60 (67%)

70/96 (73%)

  BCL6

26/38 (68%)

16/39 (41%)

20/44 (45%)

36/83 (43%)

62/121 (51%)

  CD10

7/48 (15%)

7/56 (13%)

10/48 (21%)

17/104 (16%)

24/152 (16%)

  MUM1

28/32 (88%)

30/41 (73%)

26/39 (67%)

56/80 (70%)

84/112 (75%)

  MYC

12/28 (43%)

1/1 (100%)

8/32 (25%)

9/33 (27%)

21/61 (34%)

  CD30

8/30 (27%)

4/41 (10%)

7/34 (21%)

11/75 (15%)

19/105 (18%)

  CD138

1/27 (4%)

4/38 (11%)

1/32 (3%)

5/70 (7%)

6/97 (6%)

  HHV8

0/55 (0%)

0/87 (0%)

0/60 (0%)

0/147 (0%)

0/202 (0%)

EBER-ISH

3/47 (6%)

10/66 (15%)

3/58 (5%)

13/124 (10%)

16/171 (9%)

GCB subtype

6/36 (17%)

10/44 (23%)

10/44 (23%)

20/88 (23%)

26/124 (21%)

Dual expressor

10/26 (38%)

1/2 (50%)

8/35 (23%)

9/37 (24%)

19/63 (30%)

BCL2 rearrangement

2/22 (9%)

2/7 (29%)

2/25 (8%)

4/32 (13%)

6/54 (11%)

BCL6 rearrangement

7/20 (35%)

4/12 (33%)

5/23 (22%)

9/35 (26%)

16/55 (29%)

MYC rearrangement

6/29 (21%)

11/50 (22%)

3/28 (11%)

14/78 (18%)

20/107 (19%)

Double- or triple-hit

3/25 (12%)

2/47 (4%)

1/28 (4%)

3/75 (4%)

6/100 (6%)

  1. COO cell-of-origin, EB-LBCL effusion-based large B-cell lymphoma, GCB germinal center B-cell, ISH in situ hybridization.
Back to article page